NCT02502162

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Stanford University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Conditions

• Complex Regional Pain Syndrome

Interventions

Type	Name	Description
DRUG	LDN
DRUG	Placebo	Sugar pill

Timeline

• Start date: 2015-06-01
• Primary completion: 2027-07-01
• Completion: 2027-07-01
• First posted: 2015-07-20
• Last updated: 2025-05-29

Locations

1 site across 1 country: United States